Anticancer agent 136

Compound 22 is a triazole-modified geldanamycin analog that binds Hsp90 with a Kd of 3.86 μM. It demonstrates cytotoxic activity with an IC50 of 3.38 μM in HDF cells, inducing apoptosis. This small molecule is a useful research tool for studying Hsp90 inhibition in cancer biology and apoptosis mechanisms in vitro.